July 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

An interview with Rakesh K. Jain, PhD, a cancer researcher focused on pathophysiology who helped establish the role of the tumor microenvironment in the treatment of cancer.

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

Amid a flurry of new drug approvals, the AUA has issued its first set of guidelines for the management of patients with mCRPC, which included an extensive role for abiraterone acetate at several stages of the disease.

Any lingering skepticism about immunotherapy as an anticancer strategy appears to have been banished by research presented at the 2013 ASCO Annual Meeting.

Arnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.

The biopharmaceutical industry has 241 medicines in development for the treatment of leukemia, lymphoma, myeloma, and other blood cancers, which together are expected to comprise 9%, or 150,000, of new oncologic diagnoses in America this year.

An interview with Andrew Scott, MB,BS, MD, whose work has led to the successful translation of novel potential cancer therapeutics into clinical development.

More than a century has passed since the discovery of antibodies and thanks to a number of Nobel Prize-winning scientists, we have begun to realize their potential as therapeutic tools in cancer.

The results of the first prospective multicenter trial of cryoablation in lung cancer show that this emerging treatment may be a safe, effective, and minimally invasive method of helping a specific group of patients with advanced disease.

Patients diagnosed with cancer today are considered to be genuine partners in all major treatment decisions. Yet, how well do they understand the nature and goals of genetic testing that might be recommended as part of the management of their disease?

Obinutuzumab (GA101), a novel antibody that targets CD20, demonstrated a dramatic advantage in response rates when added to chlorambucil compared with the chemotherapy agent alone in elderly patients with chronic lymphocytic leukemia.